Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Benzinga

The targeted programme found to improve IVF outcomes

Women who took part in a weight loss programme had a 21 per cent higher chance of becoming pregnant – whether naturally or through IVF

The Independent UK

Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud

As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, including Wegovy, Ozempic, and Mounjaro.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Government partners with Mounjaro maker to tackle obesity

The £85 million programme will looks at ways for patients to access services more easily.

Evening Standard

Weight loss support before IVF could boost pregnancy chances – and reduce the need for treatment

Around one in five women of childbearing age are living with [obesity], defined by the World Health Organization as having a body mass index (BMI) over 30 kg/m². Compared with women in the healthy BMI range (18.5–24.9 kg/m²), those living with obesity are three times more likely to experience fertility…

The Conversation

Ozempic and other weight-loss drugs linked to rare but serious eye conditions

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

The Conversation

Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?

Shares of Novo Nordisk A/S (NYSE:NVO) climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly (NYSE:LLY)’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Portugal tightens rules on weight loss drug prescriptions to prevent misuse

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat type 2 diabetes and obesity but are also popular for weight loss.

Euronews

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

Evening Standard

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

Five things I wish everyone knew about weight loss – by an expert in nutrition

Weight loss continues to dominate public discourse – often framed as a matter of personal responsibility. But after nearly 15 years working in and around health and nutrition research, I’ve seen how weight is treated differently from almost every other health issue.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

Euronews

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Euronews

Obesity can be passed from parents to children. But do mothers’ or fathers’ genes matter more?

A new study suggests mothers’ genes could play an indirect role in shaping their children’s health, even when they aren’t passed on.

Evening Standard

OPINION - The real problem with Ozempic? The hell that comes after

It’s not actually that hard to imagine. Have you been on a diet? Have you ever lost weight? If so, the chances are you put that weight right back on again. I’ve done it. Oprah’s done it. Sam Smith have done it. My cat did it (RIP, my boy).

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Benzinga

Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating

Imagine shedding weight while sitting quietly watching TV, even without cutting calories. A pioneering pill called SANA, created by Uruguayan startup Eolo Pharma, could one day make that possible.

The Guardian - US

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

Barchart

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

The Independent UK

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Ultra-processed baby foods ‘set children up for lifetime of obesity,’ experts warn

A study has found that one in three baby food products as classed as ultra-processed foods

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

the University of Oxford

the University of Leeds

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.